日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / State Council News

Nation issues new anti-monopoly guidelines for pharma sector

By Li Jiaying | chinadaily.com.cn | Updated: 2025-01-24 21:04
Share
Share - WeChat
Pharmacists dispense drugs at a hospital in Huzhou, Zhejiang province, in August. YI FAN/FOR CHINA DAILY

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly commission officially issued new anti-monopoly guidelines on Friday targeting the pharmaceutical sector. 

A key highlight of the guidelines lies in the involvement of online platforms' monopolistic regulations. Given the rapid growth of online medical consultations and pharmaceutical e-commerce, the guidelines, for the first time, incorporate measures to address monopolistic practices in online medicine businesses, prohibiting platforms from engaging in the misuse of data, algorithms or platform rules.

The broad scope of the new guidelines also merits attention, which encompasses the entire pharmaceutical product chain — including traditional Chinese medicine, chemical drugs and biological products — compared to the previous version, which was largely concentrated in the limited realm of chemical active pharmaceutical ingredients (APIs).

"The pharmaceutical industry is highly technology-driven. Besides APIs, it also includes innovative drugs, patented medicines and generics. Every stage — from procurement and R&D to production, distribution and generic development — involves significant technological advancements and related protective strategies," said Zhou Wei, deputy director of the health law research center at Wuhan University, in an earlier interview. 

To further combat "false innovation", the guidelines also address a new type of patent monopoly behavior known as "product hopping". 

Product hopping refers to a strategy employed by original drug manufacturers to avoid or reduce competition from generic drugs, which mostly occurs shortly before the expiration of a patented drug and the entry of its generic counterpart and if applied inappropriately, could constitute an abuse of market dominance.

Factors for evaluation include whether the new patented drug represents a non-substantial improvement and whether the transition hinders or delays the entry of generics into the market, according to the guidelines.

"This is not about restricting the development of patented drugs but about regulating false innovation that fails to significantly improve a drug's efficacy, safety or utility," Zhou said.

Comprising seven chapters and 55 articles, the guidelines aim to provide detailed interpretations of monopolistic practices, enforcement principles and criteria for determining violations, offering a comprehensive framework to tackle anti-competitive behaviors in the pharmaceutical industry.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 成人午夜网 | 伊人久久99亚洲精品久久频 | 激情综合婷婷久久 | 国产精品亚洲精品日韩已方 | 成人在线精品 | 国产精品午夜电影 | 欧美一级精品片在线看 | 九九九热在线精品免费全部 | 久久久久久久久久爱 | 久热中文字幕在线 | 久久久高清免费视频 | 美女爽到呻吟久久久久 | 91久久老司机福利精品网 | 欧美日视频 | 亚洲国产中文字幕 | 久草综合在线视频 | 成人午夜电影在线播放网站 | 精品美女在线观看视频在线观看 | 亚洲精品婷婷无码成人A片在线 | 第三级视频在线观看 | 五月婷婷亚洲 | 欧美视频在线第一页 | 亚洲欧美在线观看一区二区 | 精品黄网 | 国产成人精品久久二区二区91 | 国亚洲欧美日韩精品 | 欧美精品综合 | 特级毛片免费 | 亚洲视频免费在线播放 | 国内成人自拍视频 | 亚洲 欧美 校园 | 九一传媒在线观看 | 国产一级大片在线观看 | 成人免费毛片视频 | 色老头久久网 | 天天拍久久 | 精品国产一区二区三区香蕉沈先生 | 91啦视频在线观看 | 欧美激情第二页 | 成人精品福利 | 国产精品爱久久久久久久 |